Aileron Therapeutics (ALRN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALRN Aileron Therapeutics

Watchlist

3.3200
-0.2300-6.48%

Trading Oct 7 14:04 ET

71.93MMarket Cap-1070P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon
BenzingaSep 23 07:37 ET
Express News | Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1B Clinical Trial Evaluating Lti-03 in Idiopathic Pulmonary Fibrosis (Ipf)
ReutersSep 23 07:30 ET
Aileron Therapeutics to Present at the 8th Annual IPF Summit
PR NewswireAug 19 16:05 ET
Aileron Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results.
BenzingaAug 15 15:42 ET
Express News | Aileron Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results
BenzingaAug 15 15:42 ET
Aileron Therapeutics GAAP EPS of -$0.45
Seeking AlphaAug 15 09:39 ET

Comments

Trytosaveabit

Sep 23 06:44

Watching for data release

$Aileron Therapeutics (ALRN.US)$ Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon
Benzinga· 6 mins ago

Jaguar8

Sep 23 06:32

NEWS

$Aileron Therapeutics (ALRN.US)$
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics (NASDAQ: ALRN) has completed enrollment in Cohort 2of its ongoing Phase 1b clinical trial evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF). The trial, which enrolled a total of 24 patients, aims to assess the safety and tolerability of LTI-03 in IPF patients after 14 days of treatment...

Jaguar8

May 1 11:58

$Aileron Therapeutics (ALRN.US)$
NEWS
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

Jaguar8

May 1 11:54

$Aileron Therapeutics (ALRN.US)$
NEWS
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics, Inc. announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in IPF. Low-dose LTI-03 showed reductions in profibrotic proteins, increased expression of biomarkers, and was well-tolerated. Positive trends were observed in seven out of eight biomarkers. Data from Cohort 2 is expec...